CELLVIE wins the prestigious MedTech Innovator Value Award

CELLVIE wins the prestigious MedTech Innovator Value Award

 MedTech Innovator is the leading program for medical devices, digital health and diagnostic companies and is the largest accelerator for life science companies globally. Every year, start-ups from all over the world are invited to present their solution and vision for a chance to be selected to join the MedTech Innovator Accelerator. The program culminates in a competition for a grand prize of $350,000. The judges picking and mentoring the participating start-ups are leading life sciences industry experts, venture capitalists and successful entrepreneurs. 

2020 marked the most competitive cohort in MedTech Innovator's eight-year history, with more than 1000 companies applying. Not only was cellvie selected to join the program as one of 30 accelerator companies, but the judges picked its innovative mitochondria therapy as one of the final 5 contenders for the grand prize. Moreover, cellvie was chosen to compete for the prestigious Value Award, which is conferred based on the innovation's expected impact on patients and the healthcare system as a whole.

While the grand prize did not go to cellvie, the Value Award did. With >1,000 original applicants, this is a tremendous accomplishment, reflecting the interest and believe of industry experts in mitochondria-based therapies and its potential to emerge as a novel treatment modality. The award comes with $25,000 in prize money. More importantly, the team gained valuable insights from its mentors throughout the program and broadened its network, to accelerate cellvie's journey henceforth.


About cellvie

Founded in the US and headquartered in Zürich, Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. McCully, Schueller, del Nido and Emani in 2018. Dr. McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury, aging, and beyond. Further information can be found at

Back to news
Line art Mitochondrium